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There is an ever-growing need to control antibiotic-resistance owing to alarming resistance to commonly
available antimicrobial agents for which contemporary and alternative approaches are being explored.
The present study assessed the antibacterial activity of bacteriocins from lactic acid bacteria (LAB) from
lesser known traditionally fermented products of India for their synergistic potential with common
antibiotics against clinical b-lactamases producing pathogens. A total of 84 isolates of LAB were screened
for their antibacterial efficacy against Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli,
Klebsiella pneumoniae and Bacillus cereus as well as against clinical pathogens harbouring b-lactamase
genes such as blaCTX-M, blaVIM, blaIMP, blaSHV and blaNDM. Synergistic activity of bacteriocins were deter-
mined in combination with antibiotics namely, cefotaxime, polymyxin B, imipenem and tigecycline.
Purified bacteriocins from Lactobacillus, Pediococcus and Enterococcus inhibited the growth of b-lacta-
mase harbouring clinical pathogens which significantly higher inhibitions when compared with anti-
biotics alone. Minimum inhibitory concentration of the extracts ranged from 6.66 to 26.66 mg/ml and 10
to 33.33 mg/ml for Pediococcus pentosaceus LU11 and Lactobacillus plantarum LS6. The bacteriocinogenic
activity of LAB opens scope for bioprospection of antibacterial components in the current struggle
against increasing pandrug resistance and slowing down the expansion of multi-drug resistance.
Copyright © 2017 Institut Pertanian Bogor. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nosocomial infections have become a prime concern in the past
few decades. A nosocomial can be defined as an infection acquired
in hospital by a patient admitted for a reason other than that
infection (Ducel et al. 2002) Microorganisms such as Staphylococcus
aureus, coagulase-negative staphylococci, enterococci and those
belonging to the Enterobacteriaceae family are found to be the
source of such hospital acquired infections. The upsurge in bacterial
resistance towards antibiotics and appearance of multidrug-resis-
tant (MDR) microorganisms has been an important factor for
increasing nosocomial infections. Pathogens responsible for such
infections are found to be resistant to single or multiple antibiotics,
which demands development of new antimicrobials. In the recent
past, variety of compounds possessing antimicrobial property suchi).
nian Bogor.
r. Production and hosting by Elsas plant-derived compounds, bacteriophages and potential bacte-
ricidal compounds from bacteria have been investigated for their
activity against such MDR pathogenic strains (Singh et al. 2010;
Sulakvelidze et al. 2001). Antimicrobial peptides known as bacte-
riocins have attracted attention in this regard in the recent past
(Rapsang et al. 2011).
Bacteriocins from lactic acid bacteria (LAB) are ribosomally
synthesized antimicrobial peptides or proteins which possess
inhibitory activity towards wide range of pathogens (De Vuyst &
Leroy 2007). LAB are non-pathogenic probiotic microorganisms,
present in normal flora which exert positive influence in host
physiology and belong to the genus Lactobacillus, Enterococcus,
Pediococcus and Bifidobacterium (Martha et al. 2001; Ouwehand
et al. 2002). Studies have established the inhibitory potential of
probiotics against pathogenic strains of Salmonella, Escherichia,
Staphylococcus, Bacillus, Klebsiella and Listeria (Drago et al. 1997;
Rapsang and Joshi 2012; Rapsang et al. 2013). These probiotics
produce bacteriocins and bacteriocin-like molecules, which display
a wide range of antimicrobial activity against Gram-positive and
Gram-negative bacteria (De Vuyst & Leroy 2007).evier B.V. This is an open access article under the CC BY-NC-ND license (http://
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biotics in humans, such probiotic therapy appears to be futuristic
alternative to prevent dissemination of MDR pathogens. The
inherent properties such as low toxicity, potency, availability of
broad and narrow spectrum peptides of bacteriocins imply that they
are viable alternatives to antibiotics (Cotter et al. 2013). Studies on
lantibiotics such as nisin, lacticin 3147 belonging to the class I
bacteriocin, have shown prominent activity against Streptococcus
pneumoniae, staphylococci including methicillin-resistant Staphylo-
coccus aureus (MRSA), vancomycin-resistant enterococci (Piper et al.
2009). Bacteriocin produced by particular strain of Enterococcus
faecium against MDR bacterial species have been reported (Ali et al.
2012). The effectiveness of individual bacteriocins from potential
LAB strains could be further enhanced through combination with
other antimicrobials and commercially available antibiotics. Studies
have reported the synergistic activity of nisin with antibiotics
polymyxin E and clarithromycin against Pseudomonas aeruginosa
(Giacometti et al. 2000) and with ramoplanin and other noneb-
lactam antibiotics against various strains of MRSA and vancomycin-
resistant enterococci (Giacometti et al. 2000; Brumfitt et al. 2002).
Large variety of traditionally fermented products produced and
consumed by tribals of Northeast India are rich sources of LAB
(Thapa et al. 2004; Tamang et al. 2005; Jeyaram et al. 2010; Rapsang
et al. 2011; Taheri et al. 2011) and can be good source of probiotics
and bacteriocins. Bacteriocin like compounds from LAB associated
with traditional fermented foods to control the propagation of
clinical and food borne pathogens with probiotic therapy appears to
be an innovative alternative to reduce dissemination of pathogens.
The present study was aimed to screen bacteriocin-producing
LAB from two traditionally fermented products Tungtap (fish
product) and Tungrymbai (soybean product) and determine their
antibacterial activity alone and in combination with commercially
available antimicrobial agents against MDR pathogens and clinical
isolates.
2. Materials and Methods
2.1. Sample collection
Fifteen samples of Tungtap, a traditionally fermented Puntius
species (Figure S1) and eight samples of Tungrymbai, a traditionally
fermented soybean (Figure S2) were collected (during 2012e2015)
from retail markets of Northeast India in sterile containers andwere
transported aseptically to the laboratory for analysis within 24 h.
2.2. Isolation of LAB
The samples were homogenized using mortar and pestle. Ten
grammes of the homogenised samplewas then blended in 90mL of
0.85% (w/v NaCl) physiological saline. The total viable LAB counts in
each sample was analysed by spread plating the serially diluted
samples on de Man, Rogosa and Sharpe (MRS) agar (HiMedia,
Mumbai, India). The inoculated plates were incubated at 37C for
48e72 h for isolation of LAB (Rapsang & Joshi 2012).
2.3. Test organisms
Reference strains, Streptococcus pyogenes MTCC 1925, Entero-
coccus faecalis MTCC 2729, Escherichia coli MTCC 730, Klebsiella
pneumoniae MTCC 109 and Bacillus cereus MTCC 430 used for the
study were obtained from Institute of Microbial Technology (Mi-
crobial Type Culture Collection Centre, Chandigarh, India). Apart
from the reference strains, clinical pathogenic isolates producing
different class of b-lactamase enzymes (extended-spectrum
b-lactamases, carbapenemases) were also tested. The clinical
pathogens included K. pneumoniae (KP7, KP6) harbouring blaCTX-M,
blaNDM, Acinetobacter baumannii (AB13775) harbouring blaNDM, P.aeruginosa (PA) harbouring blaNDM, blaVIM, blaIMP and other MDR
strains of E. coli (EC, IB9, GN13, GN9) harbouring blaCTX-M, blaSHV and
blaNDM (Kumarasamy et al. 2010; Upadhaya and Joshi 2015). The
sensitivity patterns of these organisms against standard antibiotics
were previously tested using CLSI guidelines 2013 (Wayne 2013).
2.4. Screening of LAB for antimicrobial activity
Agar spot assay test (Schillinger& Lücke 1989)was carried out in
triplicate to screen the LAB isolates for their antimicrobial activity.
Each of the LAB isolatewas grown inMRS broth for 24 h at 37C. The
cultureswere then adjusted 1.5 108 CFU/mL. Tenmicrolitres of the
cell suspension from each isolate was spotted onto the surface of
MRS agar plates and incubated at 37C for 24 h. After the incubation
period, the colonies were then overlaid with 10 mL of Brain
Heart Infusion (HiMedia, Mumbai, India) soft agar containing 107
CFU/mL of indicator organisms (S. pyogenes, E. faecalis, E. coli, K.
pneumoniae and B. cereus). The plates were incubated overnight at
37C before recording the diameter of inhibition zones.
2.5. Bacteriocin production and activity
The bacterial colonies showing antibacterial activity were
selected as potential bacteriocin producers. The colonies were
subcultured in 50 mLMRS broth and incubated for 24 h at 37C in a
rotary shaker with agitation at 150 rpm. The cultures were centri-
fuged at 10,000 rpm for 30 min at 4C. A portion of the cell-free
supernatant was neutralized with 1M NaOH (pH 6.8 ± 0.2) to rule
out possible inhibition effects due to organic acids and filtered
sterilized through 0.22 mm membrane (Puradisc 25mm, India). To
determine the activity of the supernatant, agar well-diffusion
method was performed in triplicate (Singh et al. 2010). Müller-
Hinton agar (HiMedia, Mumbai, India) plates were swabbed with
bacterial cell suspension of the indicator strains and clinical path-
ogens adjusted to 1.5 108 CFU/mL. Five-millimetre diameter wells
were cut in the agar plate using a sterile cork borer. Hundred
microlitre aliquot of each supernatant was added to each well and
the plates were incubated at 37C for 24 h. After incubation, zones
of inhibition around the wells were measured manually.
2.6. Physio-chemical characterization of inhibitory
substances
2.6.1. Effect of enzymes
Aliquots of 200 mL of the cell-free supernatant were treatedwith
proteolytic enzymes such as catalase (2.6 U/mg), pepsin (16 U/mg),
proteinase K (3 U/mg), pronase E (22 U/mg) and trypsin (15 U/mg).
The assays were performed at a final concentration of 1 mg/mL and
at pH 6.5, except for pepsin (pH 3.0). Treated samples were held at
37C for 6 h. After the incubation process, samples were boiled at
100C for 5 min to stop the reaction. Untreated cell-free superna-
tant was used as control. The antimicrobial activity of the treated
and untreated supernatant was determined by agar well-diffusion
assay following the above-mentioned protocol using the selected
indicator strains.
2.6.2. Effect of temperature and different pH
To establish the effect of temperature on antibacterial activity,
aliquots of 200 mL of the cell-free supernatant were heated at 60C,
80C and 100C for 60 min and at 120C for 15 min. Aliquots of 200
mL of the cell-free supernatant were adjusted to different pH from 2
to 10 with HCl (5 M) and NaOH (5 M) and incubated for 4 h at 30C.
The residual activity was tested as described previously.
2.7. Preparation of LAB extracts
To prepare the extracts, the LAB cultures were grown at 37C for
48 h. Cell-free supernatant obtained by centrifuging the culture
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orator for 3 h at 30C. The weight of the concentrated sample was
determined and re-suspended in 0.05 M potassium phosphate
buffer (pH 7) to make desired concentration and stored at 20C
until further use.
2.8. Evaluation of synergistic effect
The efficacy of LAB bacteriocin extract alone and in combination
with commercially available antibiotics polymyxin B, tigecycline,
imipenem and cefotaxime (HiMedia, Mumbai, India) against the
MDR clinical pathogens was determined by using disc diffusion
method in triplicate. To study the combined effect of bacteriocin
extract and antibiotics, 20 mL (2 mg) of the bacteriocin extract was
added to the standard antibiotic disc which was placed on Müller-
Hinton agar plates inoculated with the test organisms. For positive
control, standard antibiotic discs were used. The plates were incu-
bated overnight at 37C and zones of inhibition were recorded. The
increase in fold area was assessed by calculating the mean surface
area of the zone of inhibition obtained by the antibiotic alone and in
combination with the bacteriocin (Birla et al. 2009). The fold area
increase for the antibiotics was calculated by the formula (b2  a2)/
a2, where a and b are the zone of inhibition for antibiotic alone and
antibiotic in combination with bacteriocin, respectively.
2.9. Determination of minimum inhibitory concentration
Minimum inhibitory concentration (MIC) of the LAB extracts was
performed in triplicate using broth microdilution method (Nath &
Joshi 2014) in 96 multiwell microtiter plates in triplicates. 0.5
McFarland standard suspension of the indicator bacteria and the
clinical isolateswere inoculated inMüller-Hintonbrothmedium. Fifty
microlitres of the inoculum was added to appropriate wellsTable 1. Antagonistic activity of the LAB isolates against indicator bacteria and clinical p
Reference strain Isolated lactic acid bacteria
LS9 LS5 GS4 KB10 KTP1
Streptococcus
pyogenes MTCC
1925
10.6± 0.334 15.3± 0.334 17.6± 0.334 13.3± 0.667 11± 0.0
Enterococcus
faecalis
MTCC 2729
10± 0.0 26.3± 0.334 25.3± 0.334 19± 0.0 15± 0.0
Escherichia coli
MTCC 730
11.3± 0.334 11.6± 0.334 18.3± 0.334 19± 0.334 12± 0.0
Klebsiella
pneumoniae
MTCC 109
10± 0.334 16± 0.0 19± 0.334 17± 0.0 10± 0.578
Bacillus cereus
MTCC 430
12± 0.0 15± 0.0 13.3± 0.667 18± 0.0 14± 0.0
Clinical pathogens
E. coli GN17 e 18± 0.0 15.3± 0.334 10.3± 0.334 10± 0.578
K. pneumoniae KP7 e 16± 0.0 12.6± 0.334 e e
E. coli GN4 e 10.6± 0.334 10.6± 0.334 e 10.3± 0.334
E. coli GN9 12.6± 0.334 18.3± 0.334 10.6± 0.334 15.3± 0.334 12.6± 0.334
E. coli GN12 10.6± 0.667 19± 0.0 15± 0.0 10.3± 0.334 15.3± 0.334
P. aeruginosa PA6 11.6± 0.334 20± 0.0 18.3±
0.334
12± 0.0 13± 0.0
E. coli GN2 e 18± 0.0 17.6±
0.334
10± 0.578 e
K. pneumoniae
KP5
e 13± 0.0 e e e
E. coli EC16 e 12.3± 0.667 11± 0.0 e 11.6± 0.334
E. coli EC49 e 11.6± 0.334 e 9.3± 0.334 e
E. coli IB9 e 11.3± 0.334 e 11.6± 0.334 e
E. coli GN13 11± 0.0 12.3± 0.667 12.3± 0.667 11.3± 0.334 e
A. baumannii
AB-13773
e 11± 0.0 e 10± 0.0 e
e Indicates no inhibition; values are mean± SEM of three replicates.
LAB¼ lactic acid bacteria; SEM¼ standard error of the mean.containing 50 mL of bacteriocin extract of different LAB in different
concentrations. The final concentrations of the extracts used to
evaluate the antibacterial activity were in the range of
3.33e66.66 mg/mL. The 96-well plates were then sealed with paraf-
ilm and incubated in aseptic condition at 37C for 18 h. One hour
before the incubationperiod, 50 mL of 0.5% solution of 2,3,5-triphenyl
tetrazolium chloride (Sigma, India) was added to the wells and the
plates were incubated for another hour in dark conditions. The col-
ourless tetrazolium salt was reduced to a red colour compound by
biologically active organisms. The inhibition of growth can be detec-
ted when the solution in the well remains clear after the incubation
with triphenyl tetrazoliumchloride. The lowest concentrationof each
extract showing no visible growth was recorded as the MIC.
2.10. Identification of bacteriocin-producing LAB
The bacterial isolates were characterized based on colony
morphology, Gram staining reaction and biochemical tests like
catalase, oxidase activity, indole production, MR-VP, nitrate
reduction, urease activity, citrate utilization and gelatin hydrolysis.
Whole genomic DNA was extracted using HiPurA Bacterial
and Yeast Genomic DNA Isolation Kit (HiMedia, Mumbai, India).
The polymerase chain reaction was carried out using universal
primer sets 27F (50-AGA GTT TGA TCC TGG CTC AG-30) and 1492R
(50-TAC GGY TAC CTT GTT ACG ACTT-30) (Thomas 2004) obtained
from IDT, India, and amplified products were purified using
QIAquick Gel Extraction Spin Kit (QIAGEN, Germany). The purified
16S rRNA gene products were sequenced using BigDye Terminator
reaction method using Genetic Analyzer ABI 3130XL (Applied Bio-
systems, USA). BLAST programme (https://blast.ncbi.nlm.nih.gov/
Blast.cgi) was performed for the analysis of 16S rRNA gene
sequence to determine the sequence homology against theathogens
KTP 5 KTP6 LS3 LS8 LU11 LS6
12.3± 0.667 11.6± 0.334 11± 0.0 10.6± 0.334 16± 0.0 e
15.3± 0.334 17.6± 0.334 12.3± 0.667 14± 0.0 21± 0.0 e
13± 0.0 14.3± 0.334 16.3± 0.334 10.6± 0.334 23± 0.0 11.6± 0.334
15.3± 0.334 15.3± 0.334 12.6± 0.334 11.3± 0.334 15± 0.0 10± 0.0
14± 0.0 11.3± 0.334 14± 0.0 e 16± 0.0 12.6± 0.334
10.3± 0.334 e 17± 0.0 e 17.6± 0.334 11.3± 0.334
e e 17± 0.0 e 21± 0.0 18± 0.0
12± 0.0 11.6± 0.334 11.3± 0.334 11.3± 0.334 10.6± 0.667 10± 0.578
11.6± 0.334 13± 0.0 16± 0.0 11.3± 0.334 17.6± 0.334 15± 0.0
14± 0.0 10.6± 0.334 19± 0.334 e 18.3±
0.334
10.6± 0.667
15.3±
0.334
14± 0.0 20.3± 0.334 13± 0.0 17.6±
0.334
9.3± 0.334
12.6± 0.334 e 21.3± 0.334 14± 0.0 20.3± 0.334 13± 0.0
e e 10.6± 0.334 e 10± 0.0 9.3± 0.334
e e 10± 0.578 10± 0.0 11.3± 0.334 11.3± 0.334
e e 10 ± 0.334 10± 0.578 11.6± 0.334 11.6± 0.334
e e 10.6± 0.334 e 12.3± 0.667 9.3± 0.334
11.6± 0.334 13.6± 0.334 11.6± 0.334 9.3± 0.334 10± 0.0 9.3± 0.334
e e 9.3± 0.334 9.3± 0.334 15.3± 0.334 18± 0.0
K. Biswas, et al90database of type strains in manually curated and validly published
prokaryotic names at the EzTaxon 2.1 server (https://www.
ezbiocloud.net/resources/16s_download) (Chun et al. 2007). Mo-
lecular Evolutionary Genetics Analysis software (MEGA version 6.0)
(http://megasoftware.net/) was used for phylogenetic analyses
(Tamura et al. 2007). The sequences retrieved from database were
alignedwith the studied isolates using ClustalW inbuilt withMEGA
6.0. To construct the phylogenetic tree, neighbour-joining method
was used with 500 bootstrap replications to assess nodal support in
the tree.3. Results
3.1. Isolation of LAB, antibacterial activity, characterization of
inhibitory substances and bacteriocin production
A total of 84 isolates of LAB were obtained from the traditionally
fermented products. Screening for the production of potential
antimicrobial bacteriocin revealed 11 isolates (13.09%) inhibiting
the growth of the indicator organisms and clinical isolates (Table 1;
Figure 1).
The isolate LS5 showed the highest zone of inhibition (26 mm)
against E. faecalis. E. coli was moderately inhibited by the bacte-
riocin with the highest zone of inhibition (23 mm) by the cell-free
extract of the isolate LU11.Figure 1. Agar well diffusion showing the bacteriocinogenic activities of representative is
Klebsiella pneumoniae MTCC 109 and (D) Escherichia coli MTCC 730. Each well contained thOf the 11 different MDR clinical pathogens tested, four bacte-
riocin-producing isolates (LS5, LS3, LU11 and LS6) exhibited anti-
bacterial activity against all the clinical pathogens (Table 1;
Figure 2). Among these, the isolates LS6 and LU11 showing high
antibacterial activity against the tested indicator strains and clinical
isolates were selected for further study.
Antibacterial activity of the cell-free supernatant showed no
activity when treated with the proteolytic enzymes except pepsin.
The inhibitory activity was not affected by the effect of catalase
indicating that the growth inhibition was not due to hydrogen
peroxide production (Table 2). The cell-free supernatant was stable
to heat treatment at 60C and 80C for 60 min. However, heating at
100C and 121C reduced the activity by 30%e50% (Table 2). The
antibacterial activity was also maintained stable over the pH range
of 2e10 (Table 2).3.2. Synergistic effect of LAB extract with antibiotics
The effect of bacteriocin extract from the isolates LU11 and LS6
alone and in combination with antibiotics against the MDR clinical
pathogens E. coli (GN9, IB9, GN13), K. pneumoniae KP7 and A.
baumannii AB13775 revealed different inhibitory effects (Table 3).
The efficacy of polymyxin B and imipenem in combination with
LU11 and LS6 extracts showed increased activity against all the
strains of E. coli and K. pneumoniae. The bacteriocin extract of the
isolate LU11 showed maximum increase in fold area of 1.086 witholates against (A) Bacillus cereus MTCC 430, (B) Enterococcus faecalis MTCC 2729, (C)
e nonepH-adjusted cell-free extract of the isolates.
Figure 2. Agar well diffusion showing the bacteriocinogenic activities of representative isolates against clinical pathogens (A) Escherichia coli, (B) Klebsiella pneumoniae and (C)
Acinetobacter baumannii.
Table 2. Physio-chemical characteristics of the bacteriocin produced by the LAB against Escherichia coli MTCC 730
Isolates Control Enzyme treatment Effect of temperature Effect of pH
Catalase Pepsin Proteinase K Pronase E Trypsin 60C 80C 100C 121C 2 4 6 8 10
LS9 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
LS5 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
GS4 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
KB10 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
KTP1 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
KTP5 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
KTP6 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
LS3 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
LS8 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
LU11 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
LS6 þþþ þþ þþ    þþþ þþþ þ þ þþ þþ þþ þþ þþ
þþþ Inhibitory zone > 10 mm; þþ inhibitory zone 7e10 mm; þ inhibitory zone 5e7 mm;  no inhibitory zone.
LAB¼ lactic acid bacteria.
Table 3. Synergistic activity of bacteriocins alone and in combination with antibiotics
Mean of zone of inhibition (mm) produced by different antibiotics without/with bacteriocin
Test
strains
PMB alone PMB with
bacteriocin
extract
Increase
in fold
area
TGC
alone
TGC with
bacteriocin
extract
Increase
in fold
area
IPM
alone
IPM with
bacteriocin
extract
Increase
in fold
area
CTX
alone
CTX with
bacteriocin
extract
Increase in
fold area
Extract
from
isolate
LU11
GN9 15.3± 0.334 16.16± 0.167 0.10± 0.003 13± 0.0 20.3± 0.334 0.57± 0.003 11± 0.0 13.3± 0.334 0.39± 0.0 e 10± 0.00 1± 0.00
IB9 17± 0.0 20.3± 0.334 0.27± 0.003 25± 0.0 32.3± 0.334 0.63± 0.003 20± 0.0 22.3± 0.334 0.21± 0.0 e 28± 0.334 1± 0.007
GN13 14± 0.0 17.3± 0.334 0.32± 0.003 21± 0.0 27.6± 0.334 0.65± 0.007 31± 0.0 31.6± 0.334 e 22± 0.0 24± 0.334 0.19± 0.003
KP7 16± 0.0 20.3± 0.334 0.36± 0.003 18± 0.0 22.6± 0.334 0.49± 0.003 11± 0.0 13.6± 0.334 0.39± 0.007 e 10± 0.00 1± 0.00
AB-13773 e e 0.00± 0.003 18± 0.0 26± 0.0 1.086± 0.0 e e 0.00 e 12± 0.334 1± 0.007
Extract
from
isolate
LS6
GN9 15.3± 0.0 17.3± 0.334 0.14± 0.007 13± 0.0 21± 0.0 1.60± 0.0 11± 0.0 16.6± 0.334 1.11± 0.003 e 13.3± 0.334 1± 0.007
IB9 17± 0.0 20.3± 0.334 0.38± 0.003 25± 0.0 31.3± 0.334 0.53± 0.0 20± 0.0 22.3± 0.334 0.21± 0.003 e 27± 0.00 1± 0.00
GN13 14± 0.0 17.3± 0.334 0.47± 0.003 21± 0.0 27.6± 0.334 0.65± 0.0 31± 0.0 31.3± 0.334 e 22± 0.0 25 0.29
KP7 16± 0.0 18.3± 0.334 0.26± 0.007 18± 0.0 24.3± 0.334 0.77± 0.003 11± 0.0 12.3± 0.334 0.19± 0.0 e 22± 0.00 1± 0.00
AB-13773 e e e 18± 0.0 24.3± 0.334 0.77± 0.003 e e e e 11± 0.00 1± 0.00
e Indicates no inhibition. Values are mean± SEM of three replicates.
PMB ¼ polymyxin B; TGC ¼ tigecycline; IPM ¼ imipenem; CTX ¼ cefotaxime; SEM¼ standard error of the mean.
Bacteriocins from LAB inhibit b-lactamase-producing pathogens 91tigecycline against A. baumannii (Figure 3). Similarly, LS6 extract
showed the highest activity in combinationwith tigecycline against
E. coli GN9 with an increase in fold area of 1.60. Cefotaxime showed
no inhibition in the growth of E. coli (GN9, IB9), K. pneumoniae
(KP7) and A. baumannii (AB13775). However, the same antibiotic
showed an increase in fold area when combined with the extracts
of LU11 and LS6 (Table 3).
3.3. Minimum inhibitory concentration
The MIC value of the extracts correlated with the well-diffusion
assay of bacteriocin activity (Table 4). The MIC of the bacteriocinextract of LU11 against E. coli MTCC 730 was 6.66 mg/mL, which
was recorded as the lowest MIC value (Table 4). For the clinical
isolates E. coli (GN9, IB9), K. pneumoniae (KP7) and A. baumannii
(AB13775), the MIC was found to be 20.33, 26.66, 13.33 and
16.66 mg/mL, respectively, with the bacteriocin extract of LU11
(Table 4). The MIC of LS6 extract was 20 mg/mL against E. coliMTCC
730 and 22.66, 18, 10 and 33.33 mg/mL against A. baumannii
AB13775, K. pneumoniae KP7 and E. coli (GN9, IB9), respectively. The
bacteriocin extract from the isolate LU11 showed lower MIC values
against E. coli MTCC 730 and the clinical pathogens A. baumannii
AB13775 as well as E. coli IB9 in comparison with LS6 (Table 4).
Figure 3. Synergistic effect of bacteriocins from the LAB isolate LU11 against clinical
pathogens A. baumannii. The effect reflects the activity of bacteriocin alone and in
combination with antibiotics tigecycline (TGCþ LU11), imipenem (IMPþ LU11) and
cefotaxime (CTXþ LU11). LAB¼ lactic acid bacteria.
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All the 11 potent bacteriocin-producing bacterial isolates were
gram positive and catalase negative. Nine isolates were rod shaped
and two were found to be cocci (Table 5). The isolates were
characterised using 16S rRNA gene sequencing approach
(Figure S3) and BLAST programme performed against the database
at EzTaxon server to identify the nearest phylogenetic neighbours.
Among the 11 bacteriocinogenic LAB isolates, Lactobacilluswas the
most predominant representing 72.7% of the isolates. Pediococcus
comprised 18.18% of the isolates, whereas Enterococcus comprisedTable 4. Minimum inhibitory concentration of bacteriocin extracts against the clinical is
LAB used for bacteriocin extract MIC* (mg/mL) for the clinical isolates
Escherichia coli
MTCC 730
Acinetobacter baumannii
AB13775
Pediococcus pentosaceus LU11 6.66± 0.003 16.66± 0.003
Lactobacillus plantarum LS6 20± 0.334 22.66± 0.003
LAB¼ lactic acid bacteria; MIC¼minimum inhibitory concentration; SEM¼ standard err
* MIC values are mean± SEM of three replicates..
Table 5. Biochemical parameters observed for the potent bacteriocin-producing LAB iso
LAB isolates Cell appearance I C O MR-VP NR U CU GH
LS9 Cocci        
LS5 Rods        
GS4 Rods    þ    
KB10 Rods        
KTP1 Rods        
KTP5 Rods        
KTP6 Rods        
LS3 Rods        
LS8 Rods        
LU11 Cocci    þ    
LS6 Rods        
þ¼ positive; ¼ negative; C¼ catalase test; CU¼ citrate utilization; GH¼ gelatin hyd
O ¼ oxidase test; U ¼ urease production, MR-VP ¼ Methyl Red, Voges-Proskauer bioche
* Validly published species in EzTaxon server..9.09% of the isolates. The bacterial isolates were found to be the
closest homolog of Lactobacillus plantarum with a similarity of
99.80% (LS5, KB10, LS8, LS6), Lactobacillus fermentum with a sim-
ilarity of 98.52% (GS4), Pediococcus pentosaceuswith a similarity of
99.32% (LS9, LU11), Lactobacillus casei with a similarity of 98.54%
(KTP1), Lactobacillus brevis with a similarity of 99.78% (KTP1,
KTP5) and Enterococcus sp. with a similarity of 97.74% (LS3)
(Table 5; Figure 4).
4. Discussion
Because of the broad spectrum of activity against bacteria and
very low toxicity to humans, b-lactam group of antibiotics are
widely used in the hospital settings for the treatment of human
diseases. These antibiotics are rendered ineffective by bacteria
producing b-lactamases, an enzyme capable of hydrolysing the b-
lactam ring. Bacteriocins from LAB have huge potential to serve as
food preservatives and also as next generation antibiotics, which
can be used to target the MDR pathogens (Perez et al. 2014). Thus,
the potential bacteriocin effective against these b-lactamase-pro-
ducing organisms could serve as an alternative option for the
treatment of hospitalized and community-based patients. In this
study, LAB that are inherent to the traditionally fermented foods
were isolated and explored for their potential to produce bacte-
riocins, which could inhibit the growth of b-lactamase-producing
clinical isolates of gram-negative bacilli.
The study revealed 13% (11 of 84) of the isolates producing
bacteriocin-like substances which could inhibit the growth of the
indicator organisms. Sezer and Güven (2009) reported that only 35
LAB isolates exhibited antibacterial activity from a total of 12,700 LAB
isolated from milk and meat products. Sharpe (2009) reported
detection of 8.7% bacteriocin-producing strains among 92 LAB iso-
lated from fresh cut vegetable products. In the present study, it was
observed that all the eleven isolateshad inhibited thegrowthofE. coli,
K. pneumoniae and B. cereus, which corroborates to earlier reports
(Mohankumar 2011; Rapsang et al. 2011, 2013). Difference in anti-
microbial activity of thedifferent isolates could bedue to thedifferentolates
Klebsiella pneumoniae KP7 Escherichia coli GN9 Escherichia coli IB9
13.33± 0.003 20.33± 0.003 26.66± 0.003
18± 0.334 10± 0.334 33.33± 0.003
or of the mean.
lates
Presumptive
identification
Closest related microorganism*
based on 16S rRNA sequences of the isolates
Similarity, %
Pediococcus spp. Pediococcus pentosaceus 99.369
Lactobacillus spp. Lactobacillus plantarum 99.796
Lactobacillus spp. Lactobacillus fermentum 98.521
Lactobacillus spp. Lactobacillus plantarum 99.836
Lactobacillus spp. Lactobacillus casei 98.545
Lactobacillus spp. Lactobacillus brevis 99.736
Lactobacillus spp. Lactobacillus brevis 99.781
Enterococcus spp. Enterococcus sp. 97.740
Lactobacillus spp. Lactobacillus plantarum 99.801
Pediococcus spp. Pediococcus pentosaceus 99.329
Lactobacillus spp. Lactobacillus plantarum 98.796
rolysis; I ¼ indole production; LAB¼ lactic acid bacteria; NR¼ nitrate reduction;
mical test.
Figure 4. Neighbour-joining tree showing the phylogenetic position of isolated strains based on 16S rDNA gene sequence. Evolutionary distance was calculated using Kimura 2-
parameter model. Bootstrap values based on 500 replicons are shown.
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heterofermentative lactobacilli (Tejero Sarinena et al. 2012).
Physio-chemical characterization of the cell-free supernatant
was carried out by treating the bacteriocin produced by the LAB
with different enzymes and also by subjecting them to different
temperature and pH ranges. Treatment of the bacteriocin withvarious proteolytic enzymes (trypsin, proteinase K, pronase E)
resulted in the loss of the antibacterial activity. This indicated
the proteinaceous nature of the compounds. Same set of pro-
teolytic enzymes also inactivated nisin (Hurst 1981) and similar
results have also been reported by Gajic et al. (1999). Bacterio-
cins are relatively heat stable molecules. The activity of the cell-
K. Biswas, et al94free supernatant was retained at various pH ranges and was not
affected by heat treatment at 80C for 60 min. The work carried
out by Lade et al. (2006) also reported that bacteriocin isolates
were stable at 100C for 10 min and bacteriocin of Lactobacillus
lactis was stable in acidic condition. Sarika et al. (2010) also re-
ported heat and pH stability of bacteriocin Lactobacillus
rhamnosus.
Because of their potential use as antimicrobial agents for
improving the safety of food products, there is an increasing in-
terest in the research of antimicrobial peptides (bacteriocins and
bacteriocin-like compounds) produced by LAB (Yildirim et al.1999).
Apart from its inhibition spectrum, technological properties like
heat and wide range of pH stability provide the bacteriocin with an
application potential as a biopreservative (Abo-Amer, 2007).
Although biochemically and genetically many bacteriocins have
been characterized, several aspects of these compounds are still
unknown (Cleveland et al. 2001), this explains why till date nisin,
approved by the Food and Drug Administration, is the only purified
bacteriocin widely used as a food preservative.
The present study also explored the antibacterial spectrum of
the LAB isolates against MDR bacterial species. There are reports on
the efficacy of the commercially available bacteriocin, nisin against
pathogenic strains of MDR S. aureus, pneumococci and MRSA
(Severina et al. 1998). The active supernatants of the potential
isolates L. plantarum LS6 and P. pentosaceus LU11 showed good
inhibitory effects against the bacteria harbouring b-lactamases.
Bacteriocins from these isolates had a broader host range against
the clinical isolates. Among the nosocomial strains used in the
study, K. pneumoniae and A. baumannii have proven to be sensitive
targets of the bacteriocin extracted from L. plantarum LS6 and P.
pentosaceus LU11. Bacteriocin extract from these isolates also
showed good inhibition activity and MIC against isolates of E. coli,
producing extended-spectrum b-lactamases and metallo-b-lacta-
mases. The MIC value of P. pentosaceus crude extract against the
gram-negative nosocomial isolate K. pneumoniae and A. baumannii
was recorded to be lower than the MIC value obtained for the
extract of L. plantarum. Jang et al. (2015) studied the activity of
P. pentosaceus T1 against Listeria monocytogenes and reported that
the MIC of this pediocin isoform (20 mg/mL) is lower than that of
nisin.
L. plantarum strains produce a broad range of bacteriocins such
as ST28MS, ST26MS, bacST202Ch, bacST216Ch, ST71KS, plantaricin
B, D, K, MG, JKZJ008, etc (Dinev et al. 2017). According to previous
studies, it is reported that L. plantarum is active against many Gram-
negative pathogens, food spoilage microorganisms and various
MDR (Dinev et al. 2017). Zang et al. (2016) reported that
L. plantarum ZDY 2013 significantly inhibited the adhesion of
enterotoxin-producing and pathogenic strains of B. cereus on
intentional epithelial cells by inhibition, competition and
displacement. The antimicrobial activity of LAB and L. plantarum
can be explained by three mechanisms: the production of bacte-
riocins; the yield of organic acids, ethanol, carbon dioxide and
hydrogen peroxide; and the competition of nutrients (Magnusson
et al. 2003). Our results showed that the strain of L. plantarum
has potential to produce antibacterial substances, which can be
viable alternative to antibiotics to treat the pandrug-resistant or-
ganisms. Kumar et al. (2016) also concluded that L. plantarum
strains which are effective against a variety of bacterial pathogens
including MRSA and MDR enteroaggregative E. coli can serve as
alternative therapeutic agents against the corresponding infections
in humans and animals.
Similar to L. plantarum, Pediococcus cultures are evident as
protective cultures against common food spoilage bacteria and
pathogens. P. pentosaceus is one of the main species used in ped-
iocin production, fermentation processes as starter culture andprobiotic supplements for humans and animals (Porto et al. 2017).
Recently, several studies have demonstrated pediocin production
from different P. pentosaceus strains such as P. pentosaceus CB4, R38,
OZF, NDCD273 (Devi and Halami 2011; Osmanagaoglu et al. 2013;
Simha et al. 2012). In a study performed by Yin et al. 2003, it was
reported that pediocin from P. pentosaceus inhibited the growth of
various Gram-negative microorganisms.
Based on the varied investigations, P. pentosaceus and L. plan-
tarum can be considered as important LAB species and the purified
form of their bacteriocins can be explored as potent antibacterial
candidate for the treatment of nosocomial infections.
One of the greatest concerns that mankind is facing today is the
rising problem of MDR pathogens and the rapidly decreasing
spectrum of antibiotics to control these pathogens. In the present
study, it was observed that the bacteriocin from the LAB alone and
in combination with polymyxin B, tigecycline, imipenem and
cefotaxime had an inhibitory activity on MDR strains of bacteria.
Although these antimicrobials cannot replace the widely used an-
tibiotics, they may serve as valuable antibiotic complements.
Traditionally fermented products harbouring a range of probiotics
LAB is a rich gene pool of organisms providing such complements.
To take advantage of these new antimicrobials in synergistic com-
bination therapy, it will be essential to determine the best possible
ratio and dosing treatment and to study the mechanism of their
activity exploring metabolomic technologies.
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